NCT01900015 - Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 3, 2014

Primary Completion Date

January 17, 2017

Study Completion Date

January 17, 2017

Conditions

HCV CoinfectionHIV Infection

Interventions

DRUG

Raltegravir

Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.

DRUG

Efavirenz

Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.

Trial Locations (10)

41014

H.U. Valme, Seville

Unknown

Hospital La Línea, La Línea de la Concepción

Hospital Universitario Reina Sofía, Córdoba

Hospital Infanta Elena, Huelva

Complejo Hospitalario de Jaen, Jaén

Hospital Universitario 12 de Octubre, Madrid

Hospital Universitario La Paz, Madrid

Hospital Regional Universitario Carlos Haya, Málaga

Hospital Universitario Virgen de la Victoria, Málaga

Hospital Universitario Virgen del Rocío, Seville

All Listed Sponsors

lead

Juan Macías

OTHER_GOV